It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular […]

A premium intraocular lens (IOL) is a type of IOL used in cataract patients that are designed to provide near, intermediate, and distance vision without glasses or contacts. In this touchOPHTHALMOLOGY interview, Dr John Hovanesian (Harvard Eye Associates CA, USA) discusses presents his Hawaiian Eye presentation on premium lens implants and the lessons on how […]

In this touchOPHTHALMOLOGY interview, Prof. Kendall Donaldson (Bascom Palmer Eye Institute, Miami, FL, USA) discusses her highlights from Hawaiian Eye which include exciting new technologies and treatments.  The abstract entitled ‘Determining Patient Priorities and Expectations for Cataract Surgery’ was presented at Hawaiian Eye and Retina meeting, 14-20 January 2023. Questions:  What presentations have excited you […]

Varenicline has been approved in the USA for the treatment of dry eye disease via the activation of tear film production. In this touchOPHTHALMOLOGY interview, Dr Cynthia Matossian (Matossian Eye Associates, New Hope, PA, USA) discusses the aims and design of her randomized, controlled, double-blinded study which evaluates tear film quality and stability in patients using varenicline […]

Identifying treatments that prevent diabetic retinopathy progression is a priority in current research. Patients with non-proliferative retinopathy currently have limited treatment options to prevent the progression of retinopathy and loss of vision, and therapies such as anti–vascular endothelial growth factor (VEGF) therapy, steroid injectable therapy and laser treatment are reserved for patients who advance to proliferative diabetic retinopathy or diabetic macular oedema (DMO). The […]

Leber hereditary optic neuropathy (LHON) is a mitochondrially inherited optic nerve disease characterized by bilateral (sequential or simultaneous), subacute, painless central vision loss.1 LHON was first described in 1871 by the German ophthalmologist Theodor Leber.2 However, it was not until 1988 that the mitochondrial mutation was discovered by Wallace et al.3 LHON is the most common hereditary mitochondrial optic neuropathy. Several primary mitochondrial […]

Reproxalap is a reactive aldehyde species (RASP) inhibitor believed to mitigate inflammatory conditions such as dry eye disease (DED), allergic conjunctivitis and uveitis.1 RASP are pro-inflammatory molecules that covalently bind to thiol and amino groups expressed on various receptors and kinases. This binding activates the pro-inflammatory signalling cascade, which involves the activation of inflammatory cytokines leading to inflammation and pro–histaminic factors leading to an allergic response.1 Malondialdehyde (MDA) […]

Biologics have redefined the outcomes of retinal pathologies by targeting the vascular endothelial growth factor (VEGF) pathway. Anti-VEGF therapy has prevented millions of people from going blind due to retinal vascular pathologies.1 Apart from preventing morbidity, it has a widespread financial benefit for patients, and the benefits seem to be huge compared with the cost […]